Third View Private Wealth LLC Buys Shares of 16,207 Illumina, Inc. $ILMN

Key Points

• Third View Private Wealth LLC bought a new stake of 16,207 shares in Illumina (NASDAQ:ILMN) during Q4, valued at about $2.13 million.
• Illumina beat Q4 estimates with $1.35 EPS (vs. $1.26 expected) and $1.16B revenue, and set FY2026 guidance of 5.050–5.200 EPS.
• Institutional investors and hedge funds own roughly 89.42% of the stock, while analysts' consensus is a Hold with a target price near $129.69 (6 Buy / 10 Hold / 2 Sell).

Third View Private Wealth LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 16,207 shares of the life sciences company's stock, valued at approximately $2,126,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ILMN. Empowered Funds LLC boosted its holdings in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock valued at $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Illumina in the 2nd quarter valued at about $621,000. CW Advisors LLC acquired a new position in Illumina in the 2nd quarter valued at about $275,000. Marshall Wace LLP boosted its holdings in Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock valued at $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC increased its position in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of Illumina stock opened at $126.96 on Tuesday. The business has a 50-day moving average of $123.67 and a 200 day moving average of $123.90. Illumina, Inc. has a 12 month low of $69.83 and a 12 month high of $155.53. The stock has a market capitalization of $19.29 billion, a price-to-earnings ratio of 23.30, a price-to-earnings-growth ratio of 2.32 and a beta of 1.49. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.10 billion. During the same period last year, the business posted $0.95 EPS. Illumina's revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Evercore set a $150.00 price objective on Illumina in a research report on Friday, February 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Illumina in a research report on Monday, December 29th. UBS Group reissued a "neutral" rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. JPMorgan Chase & Co. cut their price objective on Illumina from $130.00 to $120.00 and set a "neutral" rating for the company in a research report on Friday, February 6th. Finally, Piper Sandler cut their price objective on Illumina from $195.00 to $170.00 and set an "overweight" rating for the company in a research report on Monday, February 9th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of "Hold" and a consensus target price of $129.69.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.60% of the company's stock.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.